

Estimate change	
TP change	
Rating change	

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USDb)	845.8 / 9.6
52-Week Range (INR)	2403 / 1774
1, 6, 12 Rel. Per (%)	-3/-19/-6
12M Avg Val (INR M)	2335

Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	225.0	252.3	279.4
EBITDA	52.7	66.1	68.5
Adj. PAT	32.7	42.8	43.8
EBIT Margin (%)	18.2	21.2	19.9
Cons. Adj. EPS (INR)	71.6	94.1	96.3
EPS Gr. (%)	72.4	31.2	2.3
BV/Sh. (INR)	376.8	487.9	581.2
Ratios			
Net D:E	0.1	-0.1	-0.2
RoE (%)	20.8	21.7	18.0
RoCE (%)	17.7	18.4	16.0
Payout (%)	4.1	3.1	3.0
Valuations			
P/E (x)	25.8	19.7	19.2
EV/EBITDA (x)	16.4	12.3	11.3
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	0.2	5.6	5.1
EV/Sales (x)	3.8	3.2	2.8

Shareholding pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	46.9	46.9	47.0
DII	25.6	25.4	26.8
FII	21.3	21.5	19.3
Others	6.3	6.2	6.9

FII Includes depository receipts

CMP: INR1,852	TP: INR2,000 (+8%)	Neutral
Superior US execution drives earnings surprise		

Pipeline in inhalation/injectables/specialty products to support growth

- Lupin (LPC) exhibited better-than-expected performance with a beat of 4%/10%/23% on revenue/EBITDA/PAT in 1QFY26. This was driven by a higher-than-expected US revenue, better product mix, and lower R&D spend for the quarter.
- US sales have been on a strong uptrend for the past 14 quarters, driven by improved traction in niche products, including recent additions such as g-Jynarque (Tolvaptan) and g-Xarelto (Rivaroxaban). LPC has a strong pipeline of products in the inhalation/injectable space to sustain this growth momentum going forward. It is also working on specialty products (Namuscla, Xopenox) for the US market.
- The domestic formulation (DF) segment had a breather in YoY growth this quarter, primarily due to increased competition in one of the in-licensed products. Given its strong anti-diabetes franchise, LPC is gearing up for the launch of semaglutide as part of the first wave of market formation in India.
- LPC is also scaling additional growth drivers in India, including consumer health, diagnostics, and digital offerings for cardiac patients.
- We raise our earnings estimate by 5.5%/2% for FY26/FY27, factoring in: a) superior execution in limited competition products in the US market, b) loss of exclusivity in one of the in-licensed products in the DF market, and c) lower opex. We value LPC at 22x 12M forward earnings to arrive at a TP of INR2,000.
- LPC has achieved 3x/8x EBITDA/PAT over FY23-25. Considering the product pipeline for the US market and chronic focused approach in the Indian market, we estimate a 14%/16% EBITDA/PAT CAGR over FY25-27. Moreover, the valuation leaves limited scope for appreciation from current levels.
- Reiterate Neutral.

Robust US sales and 290bp margin expansion drive 27% YoY growth in PAT

- LPC's 1QFY26 revenue grew 11.9% YoY to INR62.7b. (our est. INR60.5b).
- US sales grew 24.3% YoY to INR24b (up 22% YoY in CC to USD282m; 39% of sales). DF sales grew 7.8% YoY to INR20.9b (34% of sales). Other developed market sales grew 17.4% YoY to INR7.7b (13% of sales). Emerging market sales grew 5.2% YoY to INR 6.5b (10% of sales).
- API sales decreased 32.9% YoY to INR2.4b (4% of sales).
- Gross Margin (GM) expanded 290bp YoY to 71.7% due to a better product mix and reduction in raw material costs.
- EBITDA margin expanded 190bp YoY to 26.2% (our est: 24.6%, largely due to a better GM. The benefit was partly offset by higher R&D spend (+150bp YoY as % of sales).
- As a result, EBITDA grew 21% YoY to INR16.4b (vs our est: INR15b).
- Adj. PAT grew 27% YoY INR11.5b (our est: INR9.3b), further supported by a lower tax rate.

Highlights from the management commentary

- LPC guided for strong double-digit YoY revenue growth, with EBITDA margin expected at 24%-25% in FY26.
- The goal dates for Risperdal Consta/Ranibizumab are Sep'25/Jun'26.
- LPC has gained considerable market share for g-Spiriva in the commercial channel and is actively working on the Medicare/Medicaid channels to further drive business from this product.
- LPC expects to launch g-Dalbavancin this year.
- Patient recruitment for Namuscla in the US market is underway, with commercialization targeted by FY29.
- Regarding Spiriva, a couple of companies have filed ANDAs for the US market.
- LPC plans to launch g-Victoza (liraglutide) in Oct'25. Pending approval of g-Victoza, the scope of USFDA approval for g-Saxenda has increased, with a goal date set for FY27.

Quarterly Performance (Consolidated)

Y/E March	FY25								FY26E				FY25	FY26E	FY26E	% Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q								
Net Sales	56,003	55,427	56,927	56,671	62,684	64,166	63,190	62,236	2,25,028	2,52,275	60,525	3.6				
YoY Change (%)	21.5	10.0	9.5	14.2	11.9	15.8	11.0	9.8	13.6	12.1	8.1					
Total Expenditure	42,389	43,059	43,162	43,750	46,269	47,803	46,508	45,557	1,72,361	1,86,137	45,636					
EBITDA	13,614	12,368	13,765	12,921	16,415	16,362	16,682	16,679	52,668	66,139	14,889	10.2				
YoY Change (%)	109.0	34.0	34.7	29.6	20.6	32.3	21.2	29.1	46.6	25.6	9.4					
Margins (%)	24.3	22.3	24.2	22.8	26.2	25.5	26.4	26.8	23.4	26.2	24.6					
Depreciation	2,477	2,569	2,715	3,932	2,990	3,259	3,209	3,161	11,693	12,618	3,074					
EBIT	11,137	9,799	11,050	8,989	13,425	13,104	13,473	13,519	40,975	53,521	11,815	13.6				
YoY Change (%)	167.3	45.1	44.5	21.3	20.5	33.7	21.9	50.4	57.7	30.6	6.1					
Margins (%)	19.9	17.7	19.4	15.9	21.4	20.4	21.3	21.7	18.2	21.2	19.5					
Interest	680	709	669	891	918	880	820	749	2,949	3,367	900					
Other Income	678	423	537	570	790	590	620	450	2,207	2,450	580					
EO Exp/(Inc)	1,204	-1,036	956	-291	-859	0	0	0	834	-859	0					
PBT	9,930	10,549	9,963	8,958	14,156	12,814	13,273	13,219	39,401	53,464	11,495	23.1				
Tax	1,875	1,954	2,124	1,135	1,941	2,447	2,588	2,604	7,087	9,581	2,127					
Rate (%)	18.9	18.5	21.3	12.7	13.7	19.1	19.5	19.7	18.0	17.9	18.5					
Minority Interest	-42	-69	-37	-99	-24	-75	-70	-72	-246	-241	-85					
Reported PAT	8,013	8,526	7,802	7,726	12,191	10,291	10,615	10,544	32,067	43,640	9,284	31.3				
Adj PAT	8,990	7,682	8,554	7,472	11,450	10,291	10,615	10,544	32,698	42,899	9,284	23.3				
YoY Change (%)	214.9	55.5	42.6	47.0	27.4	34.0	24.1	41.1	73.2	31.2	3.3					
Margins (%)	16.1	13.9	15.0	13.2	18.3	16.0	16.8	16.9	14.5	17.0	15.3					
EPS	20	17	19	16	25	23	23	23	72	94	20	23.3				

E: MOFSL estimates




Highlights from the management interaction

- LPC benefited from g-Tolvaptan for part of 1QFY26.
- Competition in mirabegron for the US market is subject to litigation outcome for peers.
- LPC witnessed additional competition in Albuterol with the entry of Amphastar.
- It has added oncology and CNS as newer focus therapies in the DF market.
- The company has a pipeline of 80 products, which are expected to be launched in the Indian market over the next five years.
- LPC received two ANDA approvals and launched three ANDAs in 1QFY26.
- It launched five brands across therapies in the DF segment in 1QFY26.
- R&D was 7.9% of sales for the quarter.
- ETR is expected to be 19% for FY26.
- Capex for the quarter was INR2b.
- Cash surplus stood at INR12.4b at the end of Jun'25


Key exhibits

Exhibit 1: US sales increased 24% YoY in 1QFY26



Source: MOFSL, Company

Exhibit 2: DF sales up 7.8% YoY in 1QFY26



Source: MOFSL, Company

US pipeline strength offsets DF weakness

US – Niche pipeline and exclusivity fuel momentum

- LPC has exhibited robust growth momentum in US generics since FY24. After delivering a 21% CAGR over FY23-25, LPC's US sales run rate continues to track upwards, with 1QFY26 sales at USD282m, up 24% YoY.
- LPC continues to add niche products to its commercial as well as development pipeline.
- Specifically, 1QFY26 has benefited from g-Jynarque (sole 180 day exclusivity), leading to the highest quarterly sales since 4QFY17.
- The company is further building its pipeline in the inhalation, injectables, and biosimilar space. It is working on the complete value chain, from the development to manufacturing of metered dose inhalers (MDIs), dry powder inhalers (DPI), soft mist inhalers, nasal sprays, and nebulizers within the respiratory segment. Likewise, it is also working on peptides, iron colloid, depot liposome, and 505b2 injectables.
- Accordingly, it is targeting about 20 complex product launches till FY28.
- It has also completed remediation measures at Tarapur/Mandideep-1.
- Given the complex nature of products, the approval timeline remains unpredictable based on historical instances. We build in a 13% sales CAGR over FY25-27 in the US segment, reaching USD1.2b.


DF – Growth moderates on LOE in in-licensed product

- After a healthy outperformance to industry in FY25, LPC's YoY growth in the DF segment has moderated to 8% in 1QFY26.
- Specifically, in prescription (Rx) segment, it grew in-line with industry for the quarter. This was partly due to the loss of a product exclusivity in the in-licensed portfolio for anti-diabetes therapy.
- Subsequently, the share of in-licensed products reduced to 6.1% of DF sales vs 12% in FY25.
- With respect to other therapies like cardiology, respiratory, gastro-intestinal and VMS, LPC delivered better-than-industry growth for the quarter.
- Based on new launches (20+ in FY26) and field force addition (to increase reach), we expect 10% sales CAGR in the DF segment over FY25-27.

Reiterate Neutral

- We raise our earnings estimate by 5.5%/2% for FY26/FY27, factoring in: a) superior execution in limited competition products in the US market, b) loss of exclusivity in one of the in-licensed products in DF market, and c) lower opex. We value LPC at 22x 12M forward earnings to arrive at a TP of INR2,000.
- LPC has achieved 3x/8x EBITDA/PAT over FY23-25. Considering the product pipeline for the US market and chronic-focused approach in the India market, we estimate 14%/16% EBITDA/PAT CAGR over FY25-27. Moreover, the valuation leaves limited scope for appreciation from current levels. Reiterate Neutral.

Exhibit 3: P/E chart



Story in charts

Exhibit 4: Revenue mix in 1QFY26




Exhibit 5: Expect 12% sales CAGR over FY25-27




Exhibit 6: R&D spending to inch up going forward




Exhibit 7: EBITDA margin to be stable over FY25-27




Exhibit 8: Expect EPS to register 16% CAGR over FY25-27





Exhibit 9: 101 ANDAs – pending approval



Source: MOFSL, Company,

Financials and valuations

Income Statement									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Net Sales	1,46,646	1,53,748	1,50,930	1,60,321	1,66,417	1,98,054	2,25,029	2,52,275	2,79,419
Change (%)	-7.2	4.8	-1.8	6.2	3.8	19.0	13.6	12.1	10.8
EBITDA	25,607	23,548	25,316	19,968	17,582	35,932	52,668	66,138	68,458
Margin (%)	17.5	15.3	16.8	12.5	10.6	18.1	23.4	26.2	24.5
Depreciation	8,461	9,702	8,874	8,220	8,807	9,956	11,693	12,618	12,891
EBIT	17,147	13,846	16,442	11,748	8,775	25,977	40,975	53,520	55,567
Int. and Finance Charges	3,025	3,630	1,406	1,428	2,743	3,116	2,949	3,367	3,043
Other Income - Rec.	3,330	3,578	1,479	1,504	757	1,218	2,207	2,450	2,550
PBT before EO item	17,452	13,794	16,515	11,824	6,790	24,079	40,234	52,603	55,074
EO Expense/(Income)	3,400	6,261	-236	25,550	-375	-147	834	0	0
PBT after EO item	14,052	7,533	16,751	-13,726	7,165	24,227	39,400	52,603	55,074
Tax	8,879	11,571	4,485	1,372	2,688	4,867	7,087	9,581	11,015
Tax Rate (%)	63.2	153.6	26.8	-10.0	37.5	20.1	18.0	18.2	20.0
Less: Minority Interest	52	-43	-101	-183	-176	-211	-246	-241	-292
Reported PAT	5,121	-3,995	12,165	-15,280	4,301	19,149	32,066	43,640	43,767
PAT Adj for EO items	6,066	10,572	11,790	8,699	3,915	18,875	32,698	42,899	43,767
Change (%)	-58.0	74.3	11.5	-26.2	-55.0	382.1	73.2	31.2	2.0
Margin (%)	4.1	6.9	7.8	5.4	2.4	9.5	14.5	17.0	15.7

Consolidated Balance Sheet									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	905	906	907	909	910	909	913	909	909
Total Reserves	1,36,517	1,24,461	1,37,124	1,20,624	1,23,695	1,41,992	1,71,122	2,20,826	2,63,264
Net Worth	1,37,422	1,25,367	1,38,031	1,21,533	1,24,605	1,42,901	1,72,035	2,21,735	2,64,173
Minority Interest	469	445	550	687	783	831	909	1,150	1,442
Deferred Liabilities	-4,457	252	496	711	738	-567	-6,053	-3,327	-3,327
Secured Loan	70,546	25,180	6,133	6,147	4,153	3,115	20,820	20,570	20,320
Unsecured Loan	15,802	24,928	30,494	37,023	42,165	26,699	34,173	29,104	25,104
Total Loans	86,347	50,108	36,627	43,170	46,318	29,814	54,993	49,675	45,425
Capital Employed	2,19,781	1,76,172	1,75,704	1,66,101	1,72,444	1,72,979	2,21,884	2,69,233	3,07,712
Gross Block	72,189	76,431	85,479	95,368	1,05,127	1,17,618	1,31,807	1,37,084	1,43,147
Less: Accum. Deprn.	23,073	32,776	41,650	49,870	58,677	68,632	80,325	92,943	1,05,833
Net Fixed Assets	49,115	43,656	43,829	45,498	46,450	48,986	51,482	44,141	37,314
Capital WIP	10,186	7,582	8,515	8,475	8,948	5,957	3,555	5,127	5,914
Investments	22,954	23,743	24,549	9,000	5,169	10,747	13,840	13,840	13,840
Goodwill & Intangibles	67,963	37,540	37,126	31,306	40,534	41,566	47,323	47,323	47,323
Curr. Assets	1,21,935	1,35,575	1,20,283	1,22,236	1,26,861	1,29,656	1,69,796	2,23,300	2,78,940
Inventory	38,368	34,569	40,920	46,307	44,918	49,539	54,764	54,261	66,652
Account Receivables	51,498	54,459	44,743	42,619	44,807	46,920	54,971	63,512	72,582
Cash and Bank Balance	9,872	24,543	17,425	10,981	12,931	12,025	31,423	76,841	1,11,020
Others	22,197	22,004	17,195	22,328	24,205	21,171	28,638	28,686	28,686
Curr. Liability & Prov.	52,372	71,924	58,598	50,414	55,519	63,931	64,111	64,498	75,617
Account Payables	41,390	59,884	47,460	42,254	46,937	54,928	57,019	57,405	68,525
Provisions	10,982	12,040	11,139	8,160	8,581	9,003	7,093	7,093	7,093
Net Current Assets	69,563	63,651	61,685	71,822	71,342	65,725	1,05,685	1,58,802	2,03,322
Appl. of Funds	2,19,781	1,76,172	1,75,704	1,66,101	1,72,444	1,72,979	2,21,884	2,69,232	3,07,712

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
EPS (Fully Diluted)	13.4	23.3	26.0	19.1	8.6	41.5	71.6	94.1	96.3
Cash EPS (Fully Diluted)	32.1	44.8	45.5	37.2	28.0	63.4	97.2	121.9	124.7
BV/Share	303.7	276.7	304.2	267.4	273.9	314.4	376.8	487.9	581.2
DPS	5.0	9.0	7.0	9.0	2.0	2.5	2.5	2.5	2.5
Payout (%)	53.3	-119.0	30.4	-31.3	24.7	6.9	4.1	3.1	3.0
Valuation (x)									
P/E (Fully Diluted)	138.0	79.4	71.2	96.7	215.0	44.5	25.8	19.7	19.2
Cash P/E (Fully Diluted)	57.6	41.3	40.6	49.7	66.2	29.2	19.0	15.2	14.8
P/BV	6.1	6.7	6.1	6.9	6.8	5.9	4.9	3.8	3.2
EV/Sales	6.3	5.6	5.7	5.4	5.3	4.3	3.8	3.2	2.8
EV/EBITDA	35.8	36.8	34.0	43.7	49.7	23.9	16.4	12.3	11.3
Return Ratios (%)									
RoE	4.4	8.0	9.0	6.7	3.2	14.1	20.8	21.7	18.0
RoCE	3.5	4.8	7.5	8.6	3.5	12.6	17.7	18.4	16.0
RoIC	3.6	5.1	9.8	9.8	3.9	14.3	21.2	25.3	25.4
Working Capital Ratios									
Asset Turnover (x)	0.7	0.9	0.9	1.0	1.0	1.1	1.0	0.9	0.9
Fixed Asset Turnover (x)	3.0	3.3	3.5	3.6	3.6	4.2	4.5	5.3	6.9
Debtor (Days)	128	129	108	97	98	86	89	92	95
Creditor (Days)	184	162	137	129	136	163	158	156	159
Inventory (Days)	95	82	99	105	99	91	89	79	87
Leverage Ratio									
Current Ratio	2.3	1.9	2.1	2.4	2.3	2.0	2.6	3.5	3.7
Interest Cover Ratio	5.7	3.8	11.7	8.2	3.2	8.3	13.9	15.9	18.3
Debt/Equity (x)	0.6	0.2	0.1	0.3	0.3	0.1	0.1	-0.1	-0.2

Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
PBT Before Extraordinary items	15,172	8,768	16,765	-13,722	7,165	24,223	40,150	66,138	68,458
Interest/Dividends Recd.	2,037	2,194	808	468	2,422	2,280	1,589	2,450	2,550
Direct Taxes Paid	-9,394	-5,112	-6,954	469	-2,432	-3,261	-9,060	-6,855	-11,015
(Inc)/Dec in WC	-5,002	-4,710	-1,925	-150	3,265	855	-14,105	-7,700	-10,341
CF from Operations	2,812	1,139	8,694	-12,936	10,420	24,098	18,573	54,034	49,652
Others	13,847	13,549	9,524	16,609	8,552	12,386	11,426	2	2
CF from Op. incl EO Exp.	16,660	14,688	18,218	3,673	18,972	36,484	29,999	54,036	49,654
(inc)/dec in FA	-9,599	-6,713	-6,714	-8,980	-14,611	-9,166	-16,531	-6,850	-6,850
Free Cash Flow	-6,786	-5,574	1,980	-21,916	-4,191	14,931	2,042	47,184	42,802
(Pur)/Sale of Investments	-20,245	-1,192	-255	15,891	3,958	-5,374	-324	0	0
Others	-2,981	18,974	-5,427	6,011	-2,214	-2,582	-24,864	0	0
CF from Investments	-32,825	11,070	-12,396	12,922	-12,868	-17,122	-41,719	-6,850	-6,850
Change in Net Worth	37	60	108	161	19	146	399	7,531	192
Inc/(Dec) in Debt	12,922	-2,674	-14,719	-11,693	700	-17,331	24,277	-5,319	-4,250
Interest Paid	-2,804	-3,562	-1,518	-1,240	-2,267	-2,829	-2,295	-3,367	-3,043
Dividend Paid	-2,248	-2,265	-2,723	-2,951	-1,825	-1,828	-3,653	-1,329	-1,329
CF from Fin. Activity	7,441	-8,906	-18,853	-15,723	-3,373	-21,842	17,319	-2,627	-8,625
Inc/Dec of Cash	-8,724	16,853	-13,031	872	2,732	-2,481	5,599	45,418	34,180
Add: Beginning Balance	14,164	5,441	22,293	9,262	9,913	12,317	9,836	15,436	60,853
Cash/Cash Eq. at end of the year	5,441	22,293	9,262	10,134	12,645	9,836	15,436	60,853	95,033
Forex/Bank	0	0	0	-221	-328	0	15,988	15,988	15,988
Closing Balance	5,441	22,293	9,262	9,913	12,317	9,836	31,423	76,841	1,11,020

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating

Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf200of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/NCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@motilaloswal.com.